ReviewHemaSphere2024

Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).

Fabio Efficace et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.